Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC).
Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016.
The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1).
mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
Future oncology (London, England). 2019 Apr 03 [Epub ahead of print]
Kyle Flannery, Marley Boyd, Jenny Black-Shinn, Nicholas Robert, Ashish M Kamat
Merck & Co., Inc., Kenilworth, NJ 07033, USA., The US Oncology Network/McKesson Specialty Health, The Woodlands, TX 77380, USA., Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.